Spondylometaphyseal dysplasia

Spondylometaphyseal dysplasia (SMD) refers to a heterogeneous group of rare skeletal disorders characterized by abnormalities affecting both the vertebrae (spondylo-) and the metaphyses of long bones. These conditions belong to the broader category of skeletal dysplasias and result in disproportionate short stature, spinal abnormalities, and limb deformities. The skeletal system is the primary body system affected, with radiographic findings typically showing platyspondyly (flattened vertebral bodies), irregular metaphyses of the long bones, and variable degrees of epiphyseal involvement. Patients may present with short-limbed or short-trunk dwarfism, genu varum (bowed legs), waddling gait, scoliosis or kyphosis, and joint limitations. Several distinct subtypes of spondylometaphyseal dysplasia have been described, including the Kozlowski type (the most common form, caused by mutations in the TRPV4 gene), the corner fracture type (Sutcliffe type), the Sedaghatian type (a severe neonatal lethal form), and the Schmidt type, among others. Each subtype has its own genetic basis, inheritance pattern, severity, and associated features. Some forms may also involve extraskeletal manifestations such as immune dysfunction, retinal abnormalities, or cardiac defects depending on the specific subtype. There is currently no cure for spondylometaphyseal dysplasia. Management is supportive and multidisciplinary, focusing on orthopedic interventions (including corrective surgery for limb deformities and spinal abnormalities), physical therapy to maintain mobility and function, pain management, and monitoring for complications. Regular follow-up with orthopedic specialists, geneticists, and other relevant specialists is recommended. Genetic counseling is important for affected families to understand the specific subtype, inheritance risk, and prognosis.

Common questions about Spondylometaphyseal dysplasia